This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (55)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Medical Practice  • Medical Practice, Other  • Drug Therapy  • Drug Therapy, Other  • Immunology  • Immunologic Disorders  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Amir Attaran, DPhil,LLB; Lee Gillespie-White, LLB

JAMA. 2001;286:1886-1892.

Public attention and debate recently have focused on access to treatment of acquired immunodeficiency syndrome (AIDS) in poor, severely affected countries, such as those in Africa. Whether patents on antiretroviral drugs in Africa are impeding access to lifesaving treatment for the 25 million Africans with human immunodeficiency virus infection is unknown. We studied the patent statuses of 15 antiretroviral drugs in 53 African countries. Using a survey method, we found that these antiretroviral drugs are patented in few African countries (median, 3; mode, 0) and that in countries where antiretroviral drug patents exist, generally only a small subset of antiretroviral drugs are patented (median and mode, 4). The observed scarcity of patents cannot be simply explained by a lack of patent laws because most African countries have offered patent protection for pharmaceuticals for many years. Furthermore, in this particular case, geographic patent coverage does not appear to correlate with antiretroviral treatment access in Africa, suggesting that patents and patent law are not a major barrier to treatment access in and of themselves. We conclude that a variety of de facto barriers are more responsible for impeding access to antiretroviral treatment, including but not limited to the poverty of African countries, the high cost of antiretroviral treatment, national regulatory requirements for medicines, tariffs and sales taxes, and, above all, a lack of sufficient international financial aid to fund antiretroviral treatment. We consider these findings in light of policies for enhancing antiretroviral treatment access in poor countries.

Author Affiliations: Center for International Development and Kennedy School of Government, Harvard University, Cambridge, Mass (Dr Attaran); International Intellectual Property Institute, Washington, DC (Ms Gillespie-White).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Do Patents Prevent Access to Drugs for HIV in Developing Countries?
Marleen Boelaert, Lut Lynen, Wim Van Damme, Robert Colebunders, Eric Goemaere, Anne-Valerie Kaninda, Laura Ciaffi, Maryline Mulemba, Ellen ‘t Hoen, Bernard Pécoul, Médecins Sans Frontières, Michael J. Selgelid, Udo Schuklenk, Amir Attaran, and Lee Gillespie-White
JAMA. 2002;287(7):840-843.
EXTRACT | FULL TEXT  

RELATED ARTICLE

October 17, 2001
JAMA. 2001;286(15):1911-1912.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Reform Proposal in Need of Reform: A Critique of Thomas Pogge's Proposal for How to Incentivize Research and Development of Essential Drugs
Sonderholm
Public Health Ethics 2009;0:php017v1-php017.
ABSTRACT | FULL TEXT  

Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases
Sonderholm
J. Med. Ethics 2009;35:315-319.
ABSTRACT | FULL TEXT  

Biomedical Patents and the Public's Health: Is There a Role for Eminent Domain?
Kesselheim and Avorn
JAMA 2006;295:434-437.
FULL TEXT  

Brazil and Access to HIV/AIDS Drugs: A Question of Human Rights and Public Health
Galvao
AJPH 2005;95:1110-1116.
ABSTRACT | FULL TEXT  

TRIPS And The Global Pharmaceutical Market
Barton
Health Aff (Millwood) 2004;23:146-154.
ABSTRACT | FULL TEXT  

How Do Patents And Economic Policies Affect Access To Essential Medicines In Developing Countries?
Attaran
Health Aff (Millwood) 2004;23:155-166.
ABSTRACT | FULL TEXT  

AIDS and Antiretroviral Drugs in South Africa: Public Health, Politics, and Individual Suffering: A Review of Brian Tilley's It's My Life
Noah
J Law Med Ethics 2003;31:144-148.
 

Patents on Drugs: Manufacturing Scarcity or Advancing Health?
Loff and Heywood
J Law Med Ethics 2002;30:621-631.
 

AIDS, Africa and indifference: a confession
Pauls Wohlgemut
CMAJ 2002;167:485-487.
FULL TEXT  

Do Patents Prevent Access to Drugs for HIV in Developing Countries?
Boelaert et al.
JAMA 2002;287:840-843.
FULL TEXT